Head-to-head comparison
Shed vs VivioMD
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Widest formulation spread in the ranking — injection, liquid drops, lozenges and a daily oral pill, plus a real brand Zepbound lane.
$199/mo sema · $299/mo tirz · Verified August 2026
Marked down on: The advertised "as low as $239" tirzepatide rate needs a twelve-month commitment — month-to-month is $299
Desk Score
VivioMD is a 50-state telehealth weight-loss program selling compounded semaglutide and compounded tirzepatide — by weekly injection or in an oral form — alongside a brand-name lane, with no price published before the assessment.
Marked down on: No price appears anywhere before the medical assessment — the homepage promises "Transparent Pricing, No Hidden Fees" without printing a figure
FDAWarning letter issued to VivioMD Group LLC dba VivioMD in June 2026. See the FDA warning-letter database.
Shed takes this head-to-head with the higher Desk Score, 88/100 (B+) against 64/100 (C) for VivioMD. VivioMD still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Shed
88/100
B+
VivioMD
64/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Shed | VivioMD |
|---|---|---|
| Semaglutide | $199/mo$199/mo month-to-month ($179/mo on the 6-month plan, $159/mo on the 12-month plan — both carry a minimum term whose shipped cycles are non-refundable) | Not listed on VivioMD's site (checked August 2026) |
| Tirzepatide | $299/mo$299/mo month-to-month ($269/mo on the 6-month plan, $239/mo on the 12-month plan — both carry a minimum term whose shipped cycles are non-refundable) | Not listed on VivioMD's site (checked August 2026) |
| Coverage | All 50 states (no state list is published on the site) | All 50 states |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | People who want a needle-free route or a brand-name option without leaving one provider. | People who want compounded semaglutide or tirzepatide, injected or oral, with free shipping and a refund if a provider declines them — and who do not mind that the price appears only after the assessment. |
| Desk Score | 88/100B+ | 64/100C |
The verdict
Desk pick — ShedShed takes this head-to-head with the higher Desk Score, 88/100 (B+) against 64/100 (C) for VivioMD. VivioMD still holds its ground where its strengths line up with yours.
Choose Shed if…
People who want a needle-free route or a brand-name option without leaving one provider.
$199/mo sema · $299/mo tirz · All 50 states (no state list is published on the site)
Choose VivioMD if…
People who want compounded semaglutide or tirzepatide, injected or oral, with free shipping and a refund if a provider declines them — and who do not mind that the price appears only after the assessment.
All 50 states
FDAWarning letter issued to VivioMD Group LLC dba VivioMD in June 2026. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Shed · VivioMD.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Shed
- CoreAge Rx vs VivioMD
- Shed vs Vaylen
- Sesame Care vs VivioMD
- Curex vs Shed
- RxSpan MD vs VivioMD
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.